In general , the vaccinations were well tolerated. Swabs were taken from the surface of the skin following injection and f rom a fluid -filled blister at one injection site and assessed for the presence of MVA- METRAP by PCR , which would have detected both live and dead virus, but none was found. Several clinical trials have since been conducted in patients with varied malignan cies, including renal, colorectal, NSCLC, prostate, and breast cancer. 27,28,29,30,31 MVA vaccines have been well tolerated in trials giving multiple doses , with a majority of adverse events reported as mild, transient, and following an expected pattern; most resolv ed within 48 hours of vaccination. MVA- BN has been used to generate 2 active cancer immunotherapies : MVA -BN-HER2 and MVA- BN-PRO. MVA- BN-HER2 expresses a modified version of the HER2 protein and has been used to treat women with HER2- positive breast cancer. MVA -BN-PRO expresses both PSA and prostatic acid phosphatase and has been used to treat men with non- metastatic prostate cancer . 23 Abbreviated Title: Phase I MVA -Brachyury -TRICOM Version Date: September 14, 2016 Confidential MVA- BN-HER2 was evaluated in 3 phase I studies, BNIT- BR-001, BNIT- BR-002, and BNIT - BR-003. In total, 45 patients were treated with single or multiple doses of vaccine and the drug was well -tolerated.